Help Us Defeat
Multiple Sclerosis & Alzheimer’s Disease
While current therapies work to slow down disease progression, we stop it in its tracks.
We are now offering a pre-IPO investment opportunity, open to accredited investors under a Regulation D offering.
Breaking Barriers. Protecting Brains.
Why Invest in Bivium?
Watch our Company Overview
Join our CEO Phil Deschamps and our scientific inventor Dr. Tara DeSilva as they take you through our mission, our vision, our scientific strategy, and our overall goal.
Bivium Biosciences' Virtual Guided Tour
0:35
1:53
1:22
1:11
2:02
1:48
1:21
0:44
2:31
1:22
get started
Become an Investor
get started
There are three main ways to initiate the process of becoming an investor:
Give us a call and speak to a member of our team to learn how you can become a member of the Bivium investor group.
1/3
Book a video call to speak to our CEO, Phil Deschamps 1-on-1 to discuss the company’s upcoming plans, overall mission, and dreams for the future.
2/3
Click the ‘Get Started’ button to receive our full investment package, offering details, and next steps for securing your place in this groundbreaking opportunity.
3/3
While other treatments slow disease progression…
We stop it in its tracks.
OFFERING TYPE:
Regulation D Offering
$1.00/SHARE
$5,000 minimum
Offering Size
$5,000,000
We’re raising up to $5M to fuel our next major inflection points across R&D and preclinical validation.
Who can invest?
Accredited Investors Only
This opportunity is through a Regulation D offering and so is open to accredited investors only.
Use of funds:
Capital will be used to support candidate identification, preclinical validation, IND-enabling studies, and regulatory submissions as we prepare our therapeutic for clinical trials.
Candidate Identification
Preclinical Validation
IND-Enabling Studies
Regulatory Submissions
Financials & Milestone Roadmap
Bivium Biosciences seeks $5M via a Regulation D offering to fund a 3-year preclinical program, aiming to our proprietary, brain-penetrant therapeutic for neurodegenerative diseases like MS and Alzheimer’s. Milestones include the generation of brain-penetrant biologic, securing feasibility data, and obtaining FDA IND approval for Phase 1 trials.
Our current milestone roadmap is depicted below.
Year 1
Generation of candidate biologic and development of in vitro target engagement assay- December 31, 2025
Years 2-3
The initial investment will be used to provide feasibility data for the brain-penetrant biologic.
Years 2-3
Further financing will be used to complete preclinical examination and submission of IND to the FDA for Phase I trials
